NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced it will present at the NIBA 153rd Investment Conference on October 7, 2026, in Fort Lauderdale, Florida. The presentation comes as the company advances its lead drug candidate, NV-387, a broad-spectrum antiviral currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox.
The timing of the conference presentation underscores the potential of NV-387 to address multiple high-consequence viral threats. The drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for measles, and NanoViricides is planning clinical trials for that indication as well as for viral acute respiratory infections. The company’s pipeline also includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS.
NanoViricides is creating special purpose nanomaterials for antiviral therapy based on its novel nanoviricide class of drug candidates and technology licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
The company’s business model centers on licensing technology from TheraCour Pharma for specific application verticals of specific viruses. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Another advanced candidate, NV-HHV-1, targets Shingles. The company is also developing drugs against oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
For investors, the NIBA conference provides a platform for NanoViricides to outline its clinical progress and strategic direction. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/vQCM4, and more information about the company is available at www.nanoviricides.com.
The announcement is being distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. As with any drug development effort, there can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
